ATP13A2

Across TCGA pan-cancer cohorts, ATP13A2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATP13A2 data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ATP13A2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATP13A2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LSCC, GBM, and LUAD are the cancer types where ATP13A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	III,IV	0.767	1.000	.010	7	view →
GBM	OS	Quartile	All	0.285	0.613	.021	4	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →
CCRCC	DFS	Median	All	0.598	1.000	.044	2	view →
PDAC	DFS	Tertile	All	0.539	0.868	.024	2	view →
HNSC	DFS	Median	IV	0.914	0.581	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATP13A2–LSCC (OS)

Open the LSCC breakdown →